drugset
drugset / Trial / NCT05357196

PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors

NCT05357196 ↗

Phase 1/2 Unknown 68 enrolled SciClone Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Phase I dose escalation period: solid tumors, including but not limited to biliary tract cancer, pancreatic cancer, ovarian cancer, thymoma, neuroendocrine carcinoma and other advanced solid tumors. Phase II trial period: biliary tract cancer

Timeline

Start
2020-04-13
Primary completion
2022-08-30
Completion
2023-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject IMIFOPLATIN Other / unclassified 150 mg/m2 —
Subject IMIFOPLATIN Other / unclassified 200 mg/m2 —
Subject IMIFOPLATIN Other / unclassified 250 mg/m2 —
Background Gemcitabine Small molecule 800 mg/m2 —
Background Gemcitabine Small molecule 1000 mg/m2 —

Indications

biliary tract cancer